Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
moxifloxacin + oleic acid refers to a novel chemical conjugate, specifically an amide derivative (often designated as 4m in research literature), where the fluoroquinolone antibiotic moxifloxacin is covalently linked to the fatty acid oleic acid. This conjugation strategy is designed to modify the drug's lipophilicity, potentially enhancing its cellular uptake and altering its biological activity. The conjugate has demonstrated potent cytotoxic effects against prostate cancer cell lines (IC50 < 5 µM) and retains significant antibacterial and antimycobacterial properties. Its primary mechanism of action involves the inhibition of bacterial DNA gyrase and topoisomerase IV, which are essential for DNA replication, though its cytotoxic activity in cancer cells suggests additional or modified pathways of action.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on moxifloxacin + oleic acid.